Back to search

National and Kapodistrian University of Athens

Μελέτη ανοσογενετικών, ανοσολογικών κλινικοεργαστηριακών νευροψυχολογικών και ψυχιατρικών δεδομένων παιδικής και εφηβικής πολλαπλής σκλήρυνσης στον Ελληνικό πληθυσμό

Abstract

dc:description

BACKGROUND - AIMS: Early-onset (pediatric and adolescent) Multiple Sclerosis (POMS) accounts for 3-5% of all MS cases. In 2007, the International Pediatric Multiple Sclerosis Study Group (IPMSSG) formed diagnostic criteria for the pediatric demyelinating diseases that were later revised in 2013. Since then, POMS has attracted the interest of the international scientific community regarding its clinical and imaging characteristics that are mostly indicative of an inflammatory rather than a degenerating profile. The Major Histocompatibility Complex (MHC), and specifically the HLA-DRB1*15:01 allele, has largely been implicated both in POMS and adult-onset MS (AOMS) pathogenesis. On the other hand, the role of auto-antibodies in POMS still remains largely unknown. Whilst earlier studies suggested a possible role of the auto-antibodies against the Myelin Oligodendrocyte Glycoprotein (MOG), MOG-related diseases are now considered a unique and separate entity. The primary objective of our study was the investigation of the clinical, imaging and laboratory characteristics of POMS patients for the first time in the Hellenic population. HLA-genotyping and antibody screening also took place in a quest for significant associations. Comparisons with AOMS and healthy controls in the healthy Hellenic population were also made.MATERIALS - METHODS: 118 POMS patients diagnosed according to the IPMSSG 2013 criteria were included in the study and followed both retrospectively and prospectively. Epidemiological (age, gender, age at disease onset, possible comorbidities), clinical (MS type, first symptom, number/rate of relapse, time of conversion from Clinically Isolated Syndrome (CIS) to CDMS, treatment, degree of disability and disability progression rate, cognitive deficits], laboratory [presence of Oligoclonal Bands in the Cerebrospinal Fluid (CSF)] and imaging (lesion distribution in brain and spinal cord) data were gathered. These characteristics were compared with those of 475 AOMS patients. A total of 72 POMS and 161 AOMS patients gave their consent for DRB1 immunogenetic typing, which was performed by a low-resolution SSO technique. Allelic frequencies were also compared with those of a sample of 246 Greek origin healthy controls, that were described in a previous study, after obtaining the appropriate permissions. 29 POMS patients gave their consent for MOG screening. Statistical analyses were conducted with the use of SPSS Inc, Chicago, IL, USA. Univariate comparisons were made using Mann–Whitney U and chi-square tests (with Yates correction for 2x2 tables) for interval and categorical variables, respectively. The Hardy–Weinberg proportions (HWPs) for HLA-DRB1 haplotypes were ascertained by using PyPoP software. Ewens–Watterson (EW) homozygosity test for neutrality was also performed. The level of statistical significance was set at 0.05. In HLA-DRB1 genotype-related tests (except those for clinical parameters), p value correction was made according to the Benjamini–Yekutieli method (or B-Y).RESULTS: The mean age of disease onset was 15.6 ±2.6 years. POMS percentage was higher in women (63.6%). The frequency of different MS types differed considerably between POMS and AOMS (p<0.001). Relapsing-remitting (RRMS) accounted for 78.8%, secondary progressive MS (SPMS) for 16.9%, primary progressive MS (PPMS) for 2.5% and relapsing progressive MS (RPMS) for 1.7%. The mean time from CIS to CDMS was shorter (27.4±34.7 months vs. 37.1 ±45.4 months, p=0.002). Regarding the presenting symptom, sensory disturbances were the most common (28.8%), followed by movement difficulties (20.7%). Major deviations from AOMS were noted in the frequency of pyramidal, sensory and also infratentorial symptoms at onset, in specific diplopia (13.5% vs 10.3%) and vertigo (6.3% vs 2.8%). The frequency of seizures was also higher (2.7% vs 0.5%). POMS patients presented lower EDSS scores (2.6±1.4 vs. 3.2±1.7, p <0.001) compared to AOMS. The disability score attributed to all functional systems was lower, except of the pyramidal function. POMS patients also had more frequent lesions of the cerebellum (70.6% vs. 57.1%, p=0.016). Positive oligoclonal bands were found in 85.9% of tested patients. No patient tested positive for MOG antibodies. Among those evaluated, 43.4% complained for fatigue, 36.4% for attention deficits, while stress was the main psychiatric comorbidity (8.8%). Younger age at POMS onset was related to higher ARR (r=-0.209, p=0.025) and lower frequencies of cervical atrophy (Z=-2.658, p=0.008), while higher EDSS scores were present in patients with brain (Z=-3.103, p=0.002) and cervical (Z=-2.792, p=0.005) atrophy. We found no correlation between the EDSS scores and the presence of lesions at these levels. Finally, earlier menses was related to higher number of relapses (r= -0.272, p=0.025) and lower EDSS progression rate (r= 0.341, p=0.005). Interferons were the first therapeutic choice in 36.4% of cases, followed by fingolimod and natalizumab in 5.1%, and dimethyl fumarate and glatiramer acetate in 4.2%. Compared to healthy controls (HC), HLA-DRB1*15 (31.9% vs. 16.7%, p=0.007) and HLA-DRB1*03 (25% vs. 12.6%, p=0.003) were more common in POMS patients. Finally, POMS HLA-DRB1*03-positive patients had higher ARR (p = 0.002), higher rates of SPMS and RPMS (33.3% vs. 22.3%, p<0.001), but not PPMS, and higher rates of brainstem lesions than HLA-DRB1*03-negative patients (OR 4.14, 95% CI 1.11–15.39, p= 0.034). CONCLUSIONS: POMS accounts for the minority of MS cases, manifesting many clinical and immunogenetic similarities but also significant differences from AOMS, that need further clarification. Most POMS patients presented with highly active relapsing MS, with a shorter interval between CIS and CDMS and a high relapse rate correlating to smaller age of POMS onset. High efficacy disease modifying treatments are often warranted to control disease activity. Nevertheless, POMS patients accrued less disability, which is positively correlated with the degree of brain and cervical atrophy, but independent of the lesion load. A finding of particular interest is the preference of the immune system of the young patients for attacking both clinically and radiologically the infra-tentorial brain regions, indicative of an immune-mediated attack on mature forms of myelin. Regarding immunogenetics, HLA-DRB1*15 and HLA-DRB1*03 were the main alleles attributing genetic risk for POMS, similarly with AOMS, highlighting the genetic homogeneity of the two disease types. In our study, HLA-DRB1*15 was not correlated with earlier disease onset. The role of HLA-DRB1*03, a well-known risk factor for NMO, seems crucial in POMS as well, as HLA-DRB1*03-positive POMS patients presented with increased risk of disease, higher disease activity and higher rates of brainstem lesions, raising the question of the putative increased role of humoral immunity in POMS pathophysiology and its putative therapeutic prospects. Moreover, HLA-DRB1*03 was associated with higher rates of SPMS and RPMS but not PPMS, indicating an inclination to neurodegeneration following or co-existing with a potent neuroinflammation. None of the study’s patients was found anti-MOG positive. The immunogenetic differences between POMS and AOMS should be further investigated by GWAS studies along with the epistatic mechanisms and parent of origin effect in the future

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Gontika, Maria
  • Γόντικα, Μαρία

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/51734

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Gontika, Maria; Γόντικα, Μαρία. Μελέτη ανοσογενετικών, ανοσολογικών κλινικοεργαστηριακών νευροψυχολογικών και ψυχιατρικών δεδομένων παιδικής και εφηβικής πολλαπλής σκλήρυνσης στον Ελληνικό πληθυσμό. National and Kapodistrian University of Athens, 2022. http://hdl.handle.net/10442/hedi/51734